Drug Database
ER

erythromycin (erythromycin, KV)

✓ Approved

Lumara Health · therapeutic agent

What is erythromycin?

erythromycin is a therapeutic agent developed by Lumara Health. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Nameserythromycin, KV
CompanyLumara Health
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Lumara Health

Therapeutic Indications

erythromycin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedMaterials horizons2026-10-15

Enhanced temperature stability of cross-linked polyethylene dielectrics enabled by a graftable molecule with multiple functional units.

Liu Ziyang Z, Meng Zhaotong Z, Wang Zhaoyang Z, Zhang Yiwei Y et al.

The temperature stability of semicrystalline polyolefin dielectrics is intrinsically linked to the interplay between crystalline morphology and charge transport, yet their coordinated regulation remains challenging. Here, a graftable molecule with multiple functional units, PXDP, was purpose-designed to coordinate crystallization and charge transport in XLPE. Its terminal vinyl group provides a grafting function, the urethane units provide hydrogen-bond-mediated ordering and nucleation, and the flexible polycaprolactone-derived segments regulate subsequent crystal growth. PXDP grafting further introduces deep traps that impede carrier migration. At a PXDP loading of 0.3 phr, the representative spherulite diameter decreases from 3.4 to 2.1 µm, accompanied by an increased conduction transition threshold and suppressed space-charge accumulation. XLPE-g-PXDP3 achieves a DC breakdown strength of 324.86 kV mm-1 at 90 °C and an electric-field distortion rate of 3.60% at 80 °C. This work establishes a multiscale molecular-design framework for coordinating crystallization and charge transport in semicrystalline polyolefin dielectrics, thereby reducing the temperature sensitivity of dielectric performance and highlighting its potential for HVDC submarine cable insulation.

PMID 42876277
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-10-15

Genomic and antimicrobial susceptibility characterization of a clinical Pasteurella aerogenes isolate from a human patient.

Chen Ying Y, Brandis Gerrit G, Li Hong H, Luo Yongjun Y et al.

Pasteurella aerogenes is an opportunistic zoonotic pathogen associated with reproductive disorders in animals and sporadic human infections. However, the complete genome, antimicrobial susceptibility profile, and phylogenetic relationships of clinical P. aerogenes isolates, particularly from China, remain poorly understood. We sequenced the complete genome of the clinical P. aerogenes isolate 21PA20240911 from a patient with urinary tract infection in Hainan, China, using a hybrid PacBio and Illumina sequencing approach. Comparative genomic analyses, including genome feature characterization, ANI-based species delineation, virulence gene screening, antimicrobial susceptibility testing, and cgSNP-based phylogenetic analysis, were performed to investigate the strains genomic landscape and evolutionary origin. The genome of strain 21PA20240911 was 2.3Mbp with a G+C content of 40.84%. ANI analysis confirmed its taxonomic assignment as P. aerogenes (97.61% identity with the reference strain). The strain carried 28 virulence-associated genes. Notably, tviB and wbpD were detected only in our strain and a duck-derived Sichuan isolate. The isolate was resistant only to erythromycin but showed nonsusceptibility to multiple β-lactams and tetracyclines. Resistance-associated determinants included tet (B)/tetR and a putative PBP3/FtsI-like protein variant carrying D350N and S357N substitutions. Phylogenetic analysis tentatively suggests the possibility of zoonotic transmission from local poultry for this strain. This study provides the first complete genome sequence of a clinical P. aerogenes isolate from China, offering a genomic foundation for understanding its pathogenicity and antimicrobial resistance. From a One Health perspective, enhanced surveillance in both clinical and veterinary settings is warranted.

PMID 42876705
Read full article →
PubMedNanomaterials (Basel, Switzerland)2026-10-14

A Nano-Bismuth-Silicone Polymer Composite as Shielding for X-Rays in Extreme-Environment Applications: Experimental and Simulation Studies.

Vaezzadeh Seyyed Saeed SS, Rahman Mahmudur M, Kota Kalyan Raj KR, Ozmaeian Masoumeh M et al.

Radiation shielding is an important consideration in the design and protection of spacecraft electronics and equipment, where conventional metallic shields can add considerable weight and are difficult to integrate with compact or non-planar components. Flexible polymer composites containing high-Z materials offer an alternative approach by combining radiation attenuation with the conformability of an elastomeric matrix. In this work, nano-bismuth is incorporated into a silicone elastomer at loadings of 0-30 wt.% to develop a flexible X-ray shielding composite. The shielding performance of the composites is evaluated experimentally under a 160 kV X-ray source at a total dose of 1 Mrad and compared using Geant4 Monte Carlo simulations. The simulation model is then used to investigate a broader range of bismuth concentrations and composite thicknesses and develop an empirical relationship to predict X-ray attenuation. The results show a clear improvement in X-ray attenuation with increasing nano-bismuth content, demonstrating the potential of silicone/nano-Bi composites as shielding materials for extreme-environment applications, including space.

PMID 42872983
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-14

Sandwich-Structured Aramid Composite Papers with Heterogeneous Dielectric Layers for Integrated Corona Resistance and Thermal Conductivity.

Ren Jun-Wen JW, Chen Jun-Xue JX, Tong Ying-Ying YY, Wang Zi Z et al.

Aramid dielectric papers are indispensable for insulation in high-performance motors for electric vehicles, aircraft, and high-speed rail. However, the ongoing electrification trend toward higher voltage, frequency, and power density imposes severe electrothermal stresses that conventional aramid papers cannot withstand. Their inherently low thermal conductivity leads to localized heat accumulation while poor corona resistance accelerates electrothermal aging, both compromising long-term motor reliability. Here, we report a sandwich-structured poly(m-phenylene isophthalamide) (PMIA) composite dielectric paper that decouples thermal conductivity from corona resistance through a functional multilayer architecture. Fluorinated graphene (FG)/PMIA surface layers provide interface passivation and charge dissipation, while boron nitride nanotube (BNNT)/PMIA core layers enable thermal conduction and dielectric reinforcement. Electrospinning followed by hot-pressing achieves spatially oriented functional filler arrangements. FG constructs continuous charge-transfer barrier to suppress surface discharge and BNNT constructs continuous thermal pathways in the bulk without compromising insulation integrity. The optimized dielectric paper achieves a thermal conductivity of 10.22 W·m- 1·K- 1 and a corona lifetime of 147.42 min, representing 1.23-fold and 14.7-fold improvements over neat PMIA paper, while maintaining a high breakdown strength of 199.52 kV/mm. This specific synergy originates from hierarchically oriented architecture rather than simple property addition, offering a universal strategy to design dielectric materials with decoupled multifunctionality.

PMID 42872470
Read full article →
PubMedRevista Argentina de microbiologia2026-10-14

Antimicrobial resistance and antibiotic therapy in patients with urinary tract infections and asymptomatic bacteriuria: A Peruvian perspective.

Castilla-Torres Nancy V NV, Castilla Jeanette J, Apayco-Espinoza Nilda A NA, Urrutia-Zegarra Alexandra A AA et al.

Overdiagnosis and overtreatment of urinary tract infections (UTIs) and asymptomatic bacteriuria (AB) increase antimicrobial resistance. The aim of this study was to evaluate resistance patterns and antibiotic therapy in patients with UTIs and AB in Peru. Cross-sectional study based on 164 urine cultures and antimicrobial susceptibility testing. A total of 62 cases of AB and 102 of UTI were identified. Women (116, 70.7%) and older adults (60, 36.6%) predominated. A total of 4582 antibiotic prescriptions were recorded, with a therapeutic pattern in both UTI and AB centered on the use of meropenem (540, 21.3%) and (333, 16.3%), vancomycin (221, 8.7%) and (454, 22.2%), ceftriaxone (369, 14.5%) and (176, 8.6%) and ceftazidime (227, 8.9%) and (274, 3.4%), respectively. In general, antibiotic therapy was bactericidal in (87, 53.0%) cases, from the surveillance group in (98, 59.8%) cases, monotherapy in (112, 68.3%) cases, and in cycles of ≤7 days. UTI was associated with a higher burden of comorbidities, including chronic renal failure, hypertension, and diabetes. Fifteen bacterial species were isolated in both clinical entities, with a predominance of Gram-negative bacilli, mainly Escherichia coli and Klebsiella pneumoniae, both of which exhibited high resistance to cephalosporins, sulfonamides, and ampicillin/sulbactam. Among Gram-positive bacteria, Enterococcus faecalis and E. faecium showed resistance to erythromycin, tetracycline, and quinolones. The widespread use of antibiotics from the surveillance group and similar antibiotic therapy in AB and UTI, revealed a critical gap in the implementation of clinical guidelines and the urgent need to accurately differentiate between the two diagnoses to avoid overprescribing and help contain bacterial resistance.

PMID 42874358
Read full article →
PubMedMatrix biology : journal of the International Society for Matrix Biology2026-10-14

Clitocine for Translational Readthrough in Junctional Epidermolysis Bullosa.

Zhang Rui R, Mabrouk Haifa El HE, Has Cristina C, Sayar Saliha Beyza SB

Junctional epidermolysis bullosa (JEB) caused by laminin-332 deficiency (JEB-LAM332) is a severe inherited skin disorder characterized by impaired dermal-epidermal adhesion, chronic wounds, and increased cancer susceptibility. The management of JEB-LAM332 is primarily symptomatic, focusing on wound care and general supportive measures; however, many therapeutic needs remain unmet. While gene and stem cell therapy has been effective in JEB-LAM332, it is not yet broadly available owing to its complexity and cost. Translational readthrough-inducing drugs (TRIDs) represent an alternative strategy for treating JEB-LAM332, given that most patients carry nonsense mutations in at least one allele of their LAMA3, LAMB3, or LAMC2 genes, with LAMB3 c.1903C>T, p.R635* (p.Arg635Ter) being the most common variant. To determine promising TRID candidates for developing readthrough therapy for JEB-LAM332 patients with LAMB3 mutations, we evaluated different classes of TRIDs and compared their efficacy against gentamicin. Erythromycin, TRID-C5 (aminoglycoside-based cocktail), artesunate and atazanavir (non-aminoglycosides, ribosomal protein RpL35 ligand) and clitocine (nucleoside analog) were tested in patient-derived keratinocytes carrying the LAMB3 nonsense variants, homozygous c.1903C>T (p.R635*) or compound heterozygous c.124C>T;c.1903C>T (p.R42*;p.R635*). We used a previously established screening platform for systematic testing of TRIDs, including immunoblotting, cell functional assays, and transcriptomics. We identified clitocine as the most potent compound for promoting translational readthrough, restoring laminin β3 chain expression and improving keratinocyte adhesion in JEB models. Clitocine treatment elicited dose- and mutation-dependent responses, while toxicity was observed at higher concentrations, particularly in normal keratinocytes. Although normal keratinocytes are not the intended therapeutic target, these findings highlight the importance of defining a therapeutic window and optimizing mutation-specific dosing. Overall, clitocine represents a potential candidate for the topical therapy of JEB-LAM332.

PMID 42874790
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about erythromycin